MacroGen gene delivery systems - Oxford BioMedica
Latest Information Update: 29 Aug 2007
At a glance
- Originator Oxford BioMedica
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 22 Nov 1999 Programme available for licensing (http://www.oxfordbiomedica.co.uk)
- 22 Nov 1999 Preclinical development for Solid tumours in United Kingdom (Unknown route)